VivoSeq
Other

Neurocognitive Function

0

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Neurocognitive Function is an early-stage landscape with 0 programs across 3 companies. The most active players are BioMarin Pharmaceutical, Pfizer, Regeneron.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

30/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalRegeneron logo

Regeneron

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Unknown status3 · 30%
Terminated2 · 20%
Withdrawn1 · 10%

Clinical Trials

Trial Activity

10 trials

Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
Completed·BioMarin Pharmaceutical logoBioMarin Pharmaceutical·Phase 3·NCT00838435·95 enrolled
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
Completed·IImperial College London·Phase 4·NCT00540137·21 enrolled
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
Completed·Regeneron logoRegeneron·Phase 4·NCT02957682·2,176 enrolled
Quality of Life and Neurocognitive Functioning
Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·N/A·NCT03257618·26 enrolled
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning.
Terminated·YYale University·Phase 1·NCT04386811·3 enrolled
Voxelotor Neurocognitive Function Study
Terminated·Pfizer logoPfizer·Phase 3·NCT05228834·1 enrolled
Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism
Withdrawn·KKirby Institute·Phase 4·NCT02292966
Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine
Unknown status·—·Phase 4·NCT03567304·28 enrolled
Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)
Unknown status·SSeverance Hospital·Phase 4·NCT01250847·83 enrolled
Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD
Unknown status·NNational Taiwan University Hospital·Phase 4·NCT02074228·120 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)